You are here: Industry Insights > Biohaven Pharmaceutical

News List

FDA Accepts sNDA Of NURTEC ODT for Preventive Treatment of Migraine americanpharmaceuticalreview
October 21, 2020
Biohaven Pharmaceutical announced the U.S. Food and Drug Administration (FDA) has filed and accepted for review its recently submitted supplemental New Drug Application (sNDA) for NURTEC™ ODT (rimegepant) for the preventive treatment of migraine.
Biohaven to Proceed with Intranasal Vazegepant Trial for COVID-19 Lung Inflammation americanpharmaceuticalreview
April 14, 2020
Biohaven Pharmaceutical announced it submitted Pre-IND/IND material to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 study of vazegepant.
Biohaven Achieves Positive Results in Trial of Migraine Treatment americanpharmaceuticalreview
April 02, 2020
Biohaven Pharmaceutical announced positive topline results in its randomized, placebo-controlled pivotal clinical trial (NCT03732638) evaluating the efficacy and safety of oral rimegepant 75 mg.
Biohaven to Advance Vazegepant into Phase 3 for Acute Treatment of Migraine americanpharmaceuticalreview
March 26, 2020
Biohaven Pharmaceutical announced a successful end of Phase 2 clinical and nonclinical interaction with the U.S. Food and Drug Administration (FDA) for intranasal vazegepant ...
Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience firstwordpharma
April 04, 2019
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced the appointment of William "BJ" Jones as Chief Commercial Officer……
Biohaven, BMS Restructure Migraine Alliance contractpharma
March 13, 2018
Biohaven Pharmaceutical is restructuring its global license agreement with Bristol-Myers Squibb Co. for Biohaven's small molecule calcitonin gene-related peptide (CGRP) receptor antagonist platform